- JPMorgan has initiated the coverage of Kymera Therapeutics Inc (NASDAQ:KYMR) with a Neutral rating and a $44 price target.
- Analyst Eric Joseph says that the Company is "relatively insulated from downside pressure versus the benchmark from a healthy balance sheet."
- At the end of 2021, Kymera held approximately $567.6 million in cash, cash equivalents, and investments.
- Joseph also adds that Kymera has limited upside potential from anticipated biomarker updates from KT-474 and the earlier stage pipeline over the mid-term.
- Kymera Therapeutics completed dose escalation in the KT-474 single-ascending dose and multiple-ascending dose portions of the Phase 1 trial.
- In December, the disclosed additional KT-474 data, with near-complete IRAK4 degradation in peripheral blood mononuclear cells (PBMC) and skin, and favorable safety profile.
- Hidradenitis suppurativa and atopic dermatitis patient cohort data expected in 2H22.
- Related: Kymera Discloses New Development Cancer Program.
- Kymera is collaborating with Sanofi SA (NASDAQ:SNY) to develop degrader candidates targeting IRAK4, including KT-474, outside of the oncology and immune-oncology fields.
- Price Action: KYMR shares are down 3.21% at $38.84 during the market session on the last check Thursday.
Get all your news in one place.
100’s of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100’s of premium titles. One news app.
JPMorgan Sees 'Limited Upside Potential' In Kymera Therapeutics' KT-474
Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member?
Sign in here
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member?
Sign in here
Our Picks